首页|丙氨酸转氨酶复常在HBeAg阳性慢性乙型肝炎抗病毒治疗中的临床价值

丙氨酸转氨酶复常在HBeAg阳性慢性乙型肝炎抗病毒治疗中的临床价值

扫码查看
目的 探讨丙氨酸转氨酶(ALT)复常对HBeAg阳性慢性乙型肝炎(CHB)患者经抗病毒治疗后的临床价值.方法 收集2013年12月-2016年11月本院收治的255例HBeAg阳性CHB初治患者.根据实验室检测,ALT水平正常值上限(ULN)为42 IU/L;按照2016年美国肝病学会(AASLD)的CHB指南推荐,男性和女性ALT ULN分别为30 IU/L和19 IU/L.以两种定义标准分别将患者分为ALT复常组和ALT未复常组,分析两组患者治疗1年时病毒学和血清学水平的变化情况以及随访5年发生肝细胞癌(HCC)的影响因素.结果 根据实验室标准,255例HBeAg阳性CHB初治患者治疗1年时ALT复常212例,未复常43例.ALT复常组HBV DNA转阴率、HBeAg血清学转换率显著高于ALT未复常组(P<0.05).根据AASLD指南标准,治疗1年时ALT复常113例,未复常142例.ALT复常组HBV DNA转阴率显著高于ALT未复常组(P<0.05).5年随访发现14例发生HCC.根据实验室标准和AASLD指南标准,ALT复常组HCC发病率分别是3.8%和1.8%,显著低于ALT未复常组的14.0%和8.5%(P<0.05).将可能影响HCC的相关风险因素进行Logistic回归分析,单因素分析显示,年龄>40岁、肝硬化、治疗1年时实验室标准和AASLD指南标准的ALT复常是HCC的风险因素,多因素分析显示,肝硬化是HCC的独立危险因素.结论 ALT复常对CHB患者病情进展与临床愈后有预测价值,抗病毒治疗早期ALT复常可降低HCC发生风险.
Clinical value of earlier alanine aminotransferase normalization during antiviral treatment in HBeAg-positive chronic hepatitis B
Objective To investigate the clinical value of alanine aminotransferase(ALT)normalization in patients with hepatitis B e antigen(HBeAg)-positive chronic hepatitis B(CHB)after antiviral therapy.Methods A total of 255 HBeAg-positive CHB treatment-naive patients admitted to our hospital from December 2013 to November 2016 were col-lected.According to laboratory testing,the upper limit of normal(ULN)for ALT levels was 42 IU/L;following the recommendations of the 2016 American Association for the Study of Liver Diseases(AASLD)CHB guidelines,the ULN for men and women were 30IU/L and 19IU/L,respectively.Patients were divided into the ALT normalization group and the ALT non-normalization group based on these two criteria,and the changes in virological and serological levels after one year of treatment and factors influencing the occurrence of hepatocellular carcinoma(HCC)during the five-year fol-low-up were analyzed.Results According to the laboratory criteria,255 HBeAg-positive CHB primary patients had 212 ALT reversions and 43 non-reversions at 1 year of treatment.the HBV DNA conversion rate and HBeAg serologic con-version rate in the ALT reversion group were significantly higher than those in the ALT non-reversion group(P<0.05).According to the criteria of AASLD guideline,at 1 year of treatment,there were 113 cases of ALT reversion and 142 ca-ses of non-reversion.The HBV DNA conversion rate of the ALT reversion group was significantly higher than that of the ALT non-reversion group(P<0.05).The 5-year follow-up found that 14 cases of HCC had occurred.According to the laboratory criteria and the criteria of AASLD guideline,the incidence rate of HCC in the ALT reversion group was 3.8%and 1.8%,which was significantly lower than that of the ALT non-reversion group(P<0.05).The incidence rate of HCC in the ALT reversion group was 3.8%and 1.8%,respectively,lower than 14.0%and 8.5%in the ALT-unre-formed group(P<0.05).Logistic regression analysis was performed to analyze the relevant risk factors that might affect HCC,and univariate analysis showed that age>40 years,cirrhosis,and ALT reversion by laboratory criteria and AASLD guideline criteria at 1 year of treatment were risk factors for HCC,and multivariate analysis showed that cirrho-sis was an independent risk factor for HCC.Conclusion ALT normalization has predictive value for disease progression and clinical outcomes in CHB patients,and early ALT normalization during antiviral treatment can reduce the risk of HCC occurrence.

Chronic hepatitis BAlanine aminotransferase normalizationAntiviral treatmentHepatocellular car-cinoma

龚红梅、李世炼、夏杰、毛青、蒋黎

展开 >

陆军军医大学第一附属医院感染病科,重庆 400038

慢乙肝 丙氨酸转氨酶复常 抗病毒治疗 肝细胞癌

2025

西部医学
四川

西部医学

影响因子:1.352
ISSN:1672-3511
年,卷(期):2025.37(1)